CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma

References

• Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225–18. doi:10.1016/j.coi.2012.01.010. PMID: 22310103.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol. 2005;23:901–44. doi:10.1146/annurev.immunol.23.021704.115816. PMID: 15771589.
   PubMed Web of Science ®Google Scholar
• Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular mechanisms of the CD47–SIRPα signalling pathway. Trends Cell Biol. 2009;19(2):72–80. doi: 10.1016/j.tcb.2008.12.001. PMID: 19144521.
   PubMed Web of Science ®Google Scholar
• Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, Tsuda M, Takada T, Kasuga M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol. 1996;16:6887–99. doi:10.1128/MCB.16.12.6887. PMID: 8943344.
   PubMed Web of Science ®Google Scholar
• Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, Carew JS, Nawrocki ST, Persky D, Anwer F. Blocking “don’t eat me” signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Rev. 2018;32:480–89. doi:10.1016/j.blre.2018.04.005. PMID: 29709247.
   PubMed Web of Science ®Google Scholar
• Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276:145–64. doi:10.1111/imr.12527. PMID: 28258703.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr., van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–99. doi:10.1016/j.cell.2009.05.045. PMID: 19632179.
   PubMed Web of Science ®Google Scholar
• Galli S, Zlobec I, Schurch C, Perren A, Ochsenbein AF, Banz Y. CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis. Leuk Res. 2015;39:749–56. doi:10.1016/j.leukres.2015.04.007. PMID: 25943033.
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109:6662–67. doi:10.1073/pnas.1121623109. PMID: 22451913.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S, Yamamoto J. et al. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 2015;4:1322–33. doi:10.1002/cam4.478. PMID: 26077800.
   PubMed Web of Science ®Google Scholar
• Yuan J, He H, Chen C, Wu J, Rao J, Yan H. Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. Cancer Cell Int. 2019;19:238. doi:10.1186/s12935-019-0957-0. PMID: 31528120.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J. et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PloS ONE. 2015;10:e0137345. doi:10.1371/journal.pone.0137345. PMID: 26390038.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS. et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610–20. doi:10.1172/JCI81603. PMID: 27294525.
   PubMed Web of Science ®Google Scholar
• Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A. et al. Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017;114:E10578–85. doi:10.1073/pnas.1710877114. PMID: 29158380.
   PubMed Web of Science ®Google Scholar
• Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V. et al. TTI-621 (SIRPalphaFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. 2017;23:1068–79. doi:10.1158/1078-0432.CCR-16-1700. PMID: 27856600.
   PubMed Web of Science ®Google Scholar
• Uno S, Kinoshita Y, Azuma Y, Tsunenari T, Yoshimura Y, Iida S, Kikuchi Y, Yamada-Okabe H, Fukushima N. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol Rep. 2007;17:1189–1194. https://www.ncbi.nlm.nih.gov/pubmed/17390064. PMID: 17390064.
   PubMed Web of Science ®Google Scholar
• Murata Y, Saito Y, Kotani T, Matozaki T. CD47-signal regulatory protein alpha signaling system and its application to cancer immunotherapy. Cancer Sci. 2018;109:2349–57. doi:10.1111/cas.13663. PMID: 29873856.
   PubMed Web of Science ®Google Scholar
• Peluso MO, Adam A, Armet CM, Zhang L, O’Connor RW, Lee BH, Lake AC, Normant E, Chappel SC, Hill JA. et al. The fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. J Immunother Cancer. 2020;8(1):e000413. doi:10.1136/jitc-2019-000413. PMID: 32345627.
   PubMed Web of Science ®Google Scholar
• Puro RJ, Bouchlaka MN, Hiebsch RR, Capoccia BJ, Donio MJ, Manning PT, Frazier WA, Karr RW, Pereira DS. Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding. Mol Cancer Ther. 2020;19:835–46. doi:10.1158/1535-7163.MCT-19-1079. PMID: 31879362.
   PubMed Web of Science ®Google Scholar
• Lin GHY, Chai V, Lee V, Dodge K, Truong T, Wong M, Johnson LD, Linderoth E, Pang X, Winston J. et al. TTI-621 (SIRPalphaFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. PloS ONE. 2017;12:e0187262. doi:10.1371/journal.pone.0187262. PMID: 29084248.
   PubMed Web of Science ®Google Scholar
• Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J. et al. Modulation of CD47-SIRPalpha innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunol Immunother. 2022;71:473–89. doi:10.1007/s00262-021-03010-6. PMID: 34247273.
   PubMed Web of Science ®Google Scholar
• Veillette A, Tang Z. Signaling regulatory protein (Sirp)alpha-CD47 blockade joins the ranks of immune checkpoint inhibition. J Clin Oncol. 2019;37:1012–14. doi:10.1200/JCO.19.00121. PMID: 30811295.
   PubMed Web of Science ®Google Scholar
• Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O’Rourke T, Narayanan S, Papadopoulos K. et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37:946–53. doi:10.1200/JCO.18.02018. PMID: 30811285.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS. et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27:2190–99. doi:10.1158/1078-0432.CCR-20-3706. PMID: 33451977.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP. et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022;101:557–69. doi:10.1007/s00277-021-04734-2. PMID: 34981142.
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Sci. 2000;288(5473):2051–54. doi: 10.1126/science.288.5473.2051. PMID: 10856220.
   PubMed Web of Science ®Google Scholar
• Olaoba OT, Ayinde KS, Lateef OM, Akintubosun MO, Lawal KA, Adelusi TI. Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPalpha-based cancer therapy. Crit Rev Oncol Hematol. 2023;184:103939. doi:10.1016/j.critrevonc.2023.103939. PMID: 36774991.
   PubMed Web of Science ®Google Scholar
• Thaker YR, Rivera I, Pedros C, Singh AR, Rivero-Nava L, Zhou H, Swanson BA, Kerwin L, Zhang Y, Gray JD. et al. A novel affinity engineered anti-CD47 antibody with improved therapeutic index that preserves erythrocytes and normal immune cells. Front Oncol. 2022;12:884196. doi:10.3389/fonc.2022.884196. PMID: 35664753.
   PubMed Web of Science ®Google Scholar
• Ma L, Zhu M, Gai J, Li G, Chang Q, Qiao P, Cao L, Chen W, Zhang S, Wan Y. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. J Nanobiotechnology. 2020;18:12. doi:10.1186/s12951-020-0571-2. PMID: 31931812.
   PubMed Web of Science ®Google Scholar
• van Bommel PE, He Y, Schepel I, Hendriks M, Wiersma VR, van Ginkel RJ, van Meerten T, Ammatuna E, Huls G, Samplonius DF. et al. CD20-selective inhibition of CD47-SIRPα “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. Oncoimmunology. 2018;7:e1386361. doi:10.1080/2162402X.2017.1386361. PMID: 29308308.
   PubMed Web of Science ®Google Scholar
• Zhang B, Li W, Fan D, Tian W, Zhou J, Ji Z, Song Y. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy. Immunology. 2022;167:15–27. doi:10.1111/imm.13498. PMID: 35575882.
   PubMed Web of Science ®Google Scholar
• Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs. 2015;7:946–56. doi:10.1080/19420862.2015.1062192. PMID: 26083076.
   PubMed Web of Science ®Google Scholar
• Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R. et al. Selective blockade of the Ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25:523–33. doi:10.1016/j.ymthe.2016.11.006. PMID: 28153099.
   PubMed Web of Science ®Google Scholar
• Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L. et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-Cell Lymphoma and leukemia. Mol Cancer Ther. 2018;17:1739–51. doi:10.1158/1535-7163.MCT-17-1095. PMID: 29743205.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14:180. doi:10.1186/s13045-021-01197-w. PMID: 34717705.
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699–713. doi:10.1016/j.cell.2010.07.044. PMID: 20813259.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL. et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Sci. 2013;341:88–91. doi:10.1126/science.1238856. PMID: 23722425.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP. et al. CD47 blockade by Hu5F9-G4 and Rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379:1711–21. doi:10.1056/NEJMoa1807315. PMID: 30380386.
   PubMed Web of Science ®Google Scholar
• Hatterer E, Barba L, Noraz N, Daubeuf B, Aubry-Lachainaye JP, von der Weid B, Richard F, Kosco-Vilbois M, Ferlin W, Shang L. et al. Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. MAbs. 2019;11:322–34. doi:10.1080/19420862.2018.1558698. PMID: 30569825.
   PubMed Web of Science ®Google Scholar
• Von Kreudenstein TS, Escobar-Carbrera E, Lario PI, D’Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH. et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs. 2013;5:646–54. doi:10.4161/mabs.25632. PMID: 23924797.
   PubMed Web of Science ®Google Scholar
• Molecule Operating Environment (MOE). [Software] 2022.02 chemical computing group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada; 2023. https://www.chemcomp.com/Research-Citing_MOE.htm.
   Google Scholar
• Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-Cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation-updated Consensus and review 2020. Front Immunol. 2020;11:1301. doi:10.3389/fimmu.2020.01301. PMID: 32695107.
   PubMed Web of Science ®Google Scholar
• Leclair P, Liu CC, Monajemi M, Reid GS, Sly LM, Lim CJ. CD47-ligation induced cell death in T-acute lymphoblastic leukemia. Cell Death Disease. 2018;9:544. doi:10.1038/s41419-018-0601-2. PMID: 29748606.
   PubMed Web of Science ®Google Scholar
• Leclair P, Lim CJ. CD47 (cluster of differentiation 47): an anti-phagocytic receptor with a multitude of signaling functions. Anim Cells Syst (Seoul). 2020;24:243–52. doi:10.1080/19768354.2020.1818618. PMID: 33224442.
   PubMed Web of Science ®Google Scholar
• Cao A, Yi J, Tang X, Szeto CW, Wu R, Wan B, Fang X, Li S, Wang L, Wang L. et al. CD47-blocking antibody ZL-1201 promotes tumor-associated macrophage phagocytic activity and enhances the efficacy of the therapeutic antibodies and chemotherapy. Cancer Res Commun. 2022;2:1404–17. doi:10.1158/2767-9764.CRC-22-0266. PMID: 36970051.
   PubMedGoogle Scholar
• Yang J, Song Y, Li Z, Zhang M, Zhou K, Wang Z, Jing H, Yu L, Ma H, Zhao X. et al. Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2023;41:7527–7527. doi:10.1200/JCO.2023.41.16_suppl.7527.
   Web of Science ®Google Scholar
• Vulto AG. Biologicals and biosimilars in hematology: the case of Rituximab. Hemasphere. 2019;3:e322. doi:10.1097/HS9.0000000000000322. PMID: 31976491.
   PubMed Web of Science ®Google Scholar
• Enqvist M, Jacobs B, Junlen HR, Schaffer M, Melen CM, Friberg D, Wahlin BE, Malmberg KJ. Systemic and intra-nodal activation of NK cells after rituximab monotherapy for Follicular Lymphoma. Front Immunol. 2019;10:2085. doi:10.3389/fimmu.2019.02085. PMID: 31572357.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001. doi:10.1023/A:1008416911099. PMID: 9818074.
   PubMed Web of Science ®Google Scholar
• Yu J, Li S, Chen D, Liu D, Guo H, Yang C, Zhang W, Zhang L, Zhao G, Tu X. et al. IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPalpha, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPalpha interaction and fcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia. 2023;37:695–98. doi:10.1038/s41375-022-01805-9. PMID: 36575242.
   PubMed Web of Science ®Google Scholar
• Ryan AM, Sokolowski SA, Ng CK, Shirai N, Collinge M, Shen AC, Arrington J, Radi Z, Cummings TR, Ploch SA. et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera(r)). Toxicol Pathol. 2014;42:1069–81. doi:10.1177/0192623313520351. PMID: 24604381.
   PubMed Web of Science ®Google Scholar